Radiation
Y^90 Radioembolization
Y^90 Radioembolization is a radiation therapy with 4 clinical trials. Currently 3 active trials ongoing.
Total Trials
4
Max Phase
—
Type
RADIATION
Molecule
—
Success Metrics
Active Trials
3(75%)
Phase Distribution
Ph phase_4
1
25%
Ph phase_2
1
25%
Ph early_phase_1
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Other(1)
Detailed Status
Recruiting2
unknown1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)
Trials by Status
recruiting250%
unknown125%
active_not_recruiting125%
Recent Activity
3 active trials
Showing 4 of 4
recruiting
Optimizing Y90 Therapy for Radiation Lobectomy
NCT04390724
recruitingphase_4
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
NCT07059494
active_not_recruitingphase_2
Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma
NCT03033446
unknownearly_phase_1
Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
NCT03099564
Clinical Trials (4)
Showing 4 of 4 trials
NCT04390724
Optimizing Y90 Therapy for Radiation Lobectomy
NCT07059494Phase 4
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
NCT03033446Phase 2
Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma
NCT03099564Early Phase 1
Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
All 4 trials loaded
Drug Details
- Intervention Type
- RADIATION
- Total Trials
- 4